Rethinking Tacrolimus Targets in the PTCy Era

https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/20/20/07/20200745-80b5-2a8a-6f6a-ccd64c86a437/mza_5050217037122635137.jpg/600x600bb.jpg

ASTCT Talks

ASTCT

65 episodes

1 day ago

ASTCT Talks is the official podcast of the American Society for Transplantation and Cellular Therapy (ASTCT). We chat with industry leaders from all areas of the blood and marrow transplantation and cellular therapy field, including doctors, physician assistants, pharmacists, nurses, administrators, social workers, and more. We hope you enjoy listening!

Medicine

Health & Fitness

RSS

All content for ASTCT Talks is the property of ASTCT and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Medicine

Health & Fitness

https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_nologo/10570906/10570906-1714156932227-b584a6194311e.jpg

Rethinking Tacrolimus Targets in the PTCy Era

ASTCT Talks

13 minutes 5 seconds

5 months ago

Rethinking Tacrolimus Targets in the PTCy Era

In this episode of ASTCT Talks, Dr. Shernan Holtan welcomes Andrew Lin, Manager of Clinical Pharmacy Services of Adult BMT and CTS at Memorial Sloan Kettering Cancer Center, to discuss the evolving role of tacrolimus levels in GVHD prophylaxis within the post-transplant cyclophosphamide (PTCy) era. They explore findings from a recent retrospective study examining whether higher tacrolimus levels offer added protection against GVHD, what this means for toxicity and patient outcomes and how these insights are shaping dosing strategies. The conversation also looks ahead to future research areas, including MMF optimization and the potential for simplified, patient-centered prophylaxis regimens.